In principle, better strength and efficiency of the nilotinib analogue that presents zero or minimal connections with P-gp and ABCG2 but nonetheless inhibits the kinase (although with lower performance) might outweigh the advantage of using the parent nilotinib drug, which inhibits the kinase but also interacts efficiently with ABCG2 and P-gp
In principle, better strength and efficiency of the nilotinib analogue that presents zero or minimal connections with P-gp and ABCG2…